重新审视肺动脉高压的致病概念--多代人的视角。

IF 5.9 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
Grazyna Kwapiszewska, Christopher Rhodes, Marlene Rabinovitch, Catherine Simpson, Paul Hassoun, Kenzo Ichimura, Marc Humbert, Edda Spiekerkoetter
{"title":"重新审视肺动脉高压的致病概念--多代人的视角。","authors":"Grazyna Kwapiszewska, Christopher Rhodes, Marlene Rabinovitch, Catherine Simpson, Paul Hassoun, Kenzo Ichimura, Marc Humbert, Edda Spiekerkoetter","doi":"10.1165/rcmb.2024-0519PS","DOIUrl":null,"url":null,"abstract":"<p><p>The rapid advancement of next-generation omics platforms, bioinformatic data analysis, and novel imaging techniques is transforming biomedical research, especially in pulmonary hypertension. These cutting-edge tools generate vast data, leading to innovative therapeutic and diagnostic possibilities, such as personalized medicine and patient-specific risk stratification. However, while embracing new technologies, it is crucial to integrate decades of hypothesis-driven research with emerging discovery platforms to avoid redundant efforts and enhance scientific progress. At the 2024 American Thoracic Society (ATS) conference, senior and junior investigators in vascular biology, pulmonary hypertension, and right heart failure engaged in pro/con debates on research paradigms. These discussions explored how evolving disease frameworks fit within the context of traditional research, emphasizing the balance between newer multi-omics approaches and classical hypothesis-driven science. Three key objectives were addressed: (1) integrating unbiased analytic methods with traditional frameworks, (2) interpreting new multi-omics findings within known pathobiological pathways, and (3) reviewing modern imaging methods for the right ventricle to improve disease understanding. While omics approaches offer a broad, integrative view and support personalized medicine, they present challenges, such as managing large datasets and ensuring effective clinical translation. Conversely, traditional reductionist approaches, focusing on known genetic alterations and signaling pathways, have led to significant breakthroughs, including the development of current therapies. Combining both approaches holds great potential to drive future discoveries and develop more effective treatments for pulmonary hypertension, a goal that can only be achieved through coordinated, transdisciplinary teams of investigators with diverse skillsets and knowledge working together to advance the field.</p>","PeriodicalId":7655,"journal":{"name":"American Journal of Respiratory Cell and Molecular Biology","volume":" ","pages":""},"PeriodicalIF":5.9000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pathogenic Concepts in Pulmonary Arterial Hypertension Revisited - A Multigenerational Perspective.\",\"authors\":\"Grazyna Kwapiszewska, Christopher Rhodes, Marlene Rabinovitch, Catherine Simpson, Paul Hassoun, Kenzo Ichimura, Marc Humbert, Edda Spiekerkoetter\",\"doi\":\"10.1165/rcmb.2024-0519PS\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The rapid advancement of next-generation omics platforms, bioinformatic data analysis, and novel imaging techniques is transforming biomedical research, especially in pulmonary hypertension. These cutting-edge tools generate vast data, leading to innovative therapeutic and diagnostic possibilities, such as personalized medicine and patient-specific risk stratification. However, while embracing new technologies, it is crucial to integrate decades of hypothesis-driven research with emerging discovery platforms to avoid redundant efforts and enhance scientific progress. At the 2024 American Thoracic Society (ATS) conference, senior and junior investigators in vascular biology, pulmonary hypertension, and right heart failure engaged in pro/con debates on research paradigms. These discussions explored how evolving disease frameworks fit within the context of traditional research, emphasizing the balance between newer multi-omics approaches and classical hypothesis-driven science. Three key objectives were addressed: (1) integrating unbiased analytic methods with traditional frameworks, (2) interpreting new multi-omics findings within known pathobiological pathways, and (3) reviewing modern imaging methods for the right ventricle to improve disease understanding. While omics approaches offer a broad, integrative view and support personalized medicine, they present challenges, such as managing large datasets and ensuring effective clinical translation. Conversely, traditional reductionist approaches, focusing on known genetic alterations and signaling pathways, have led to significant breakthroughs, including the development of current therapies. Combining both approaches holds great potential to drive future discoveries and develop more effective treatments for pulmonary hypertension, a goal that can only be achieved through coordinated, transdisciplinary teams of investigators with diverse skillsets and knowledge working together to advance the field.</p>\",\"PeriodicalId\":7655,\"journal\":{\"name\":\"American Journal of Respiratory Cell and Molecular Biology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.9000,\"publicationDate\":\"2025-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Respiratory Cell and Molecular Biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1165/rcmb.2024-0519PS\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Respiratory Cell and Molecular Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1165/rcmb.2024-0519PS","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

下一代组学平台、生物信息学数据分析和新型成像技术的快速发展正在改变生物医学研究,特别是在肺动脉高压方面。这些尖端工具产生大量数据,带来创新的治疗和诊断可能性,例如个性化医疗和针对特定患者的风险分层。然而,在接受新技术的同时,将几十年的假设驱动研究与新兴的发现平台结合起来,以避免重复的努力,促进科学进步,这一点至关重要。在2024年美国胸科学会(ATS)会议上,血管生物学、肺动脉高压和右心衰的高级和初级研究人员就研究范式进行了赞成或反对的辩论。这些讨论探讨了不断发展的疾病框架如何适应传统研究的背景,强调了新的多组学方法和经典假设驱动科学之间的平衡。三个关键目标是:(1)将无偏分析方法与传统框架相结合;(2)在已知的病理生物学途径中解释新的多组学发现;(3)回顾右心室的现代成像方法,以提高对疾病的理解。虽然组学方法提供了广泛、综合的观点并支持个性化医疗,但它们也带来了挑战,例如管理大型数据集和确保有效的临床翻译。相反,传统的还原论方法,专注于已知的遗传改变和信号传导途径,已经带来了重大突破,包括目前治疗方法的发展。结合这两种方法具有巨大的潜力,可以推动未来的发现和开发更有效的肺动脉高压治疗方法,这一目标只能通过具有不同技能和知识的跨学科研究团队的协调来实现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pathogenic Concepts in Pulmonary Arterial Hypertension Revisited - A Multigenerational Perspective.

The rapid advancement of next-generation omics platforms, bioinformatic data analysis, and novel imaging techniques is transforming biomedical research, especially in pulmonary hypertension. These cutting-edge tools generate vast data, leading to innovative therapeutic and diagnostic possibilities, such as personalized medicine and patient-specific risk stratification. However, while embracing new technologies, it is crucial to integrate decades of hypothesis-driven research with emerging discovery platforms to avoid redundant efforts and enhance scientific progress. At the 2024 American Thoracic Society (ATS) conference, senior and junior investigators in vascular biology, pulmonary hypertension, and right heart failure engaged in pro/con debates on research paradigms. These discussions explored how evolving disease frameworks fit within the context of traditional research, emphasizing the balance between newer multi-omics approaches and classical hypothesis-driven science. Three key objectives were addressed: (1) integrating unbiased analytic methods with traditional frameworks, (2) interpreting new multi-omics findings within known pathobiological pathways, and (3) reviewing modern imaging methods for the right ventricle to improve disease understanding. While omics approaches offer a broad, integrative view and support personalized medicine, they present challenges, such as managing large datasets and ensuring effective clinical translation. Conversely, traditional reductionist approaches, focusing on known genetic alterations and signaling pathways, have led to significant breakthroughs, including the development of current therapies. Combining both approaches holds great potential to drive future discoveries and develop more effective treatments for pulmonary hypertension, a goal that can only be achieved through coordinated, transdisciplinary teams of investigators with diverse skillsets and knowledge working together to advance the field.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.20
自引率
3.10%
发文量
370
审稿时长
3-8 weeks
期刊介绍: The American Journal of Respiratory Cell and Molecular Biology publishes papers that report significant and original observations in the area of pulmonary biology. The focus of the Journal includes, but is not limited to, cellular, biochemical, molecular, developmental, genetic, and immunologic studies of lung cells and molecules.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信